MedTrace Logo

TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis

NCT01556282 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2014-05-28

No results posted yet for this study

Summary

Therasphere will be administered via catheter through the Hepatic Artery to treat patients with Hepatocellular Carcinoma and Portal vein Thrombosis.

Conditions

Interventions

DEVICE

TheraSphere

TheraSphere are microspheres with y-90 a radioactive material that will be injected into the liver through a blood vessel.

Sponsors & Collaborators

  • Emory University

    lead OTHER

Principal Investigators

  • Hyun s Kim, MD · Emory University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01556282 on ClinicalTrials.gov